Who Paid My Doc
John Freeman
Pediatrics Nampa, ID Medical Doctor
NPI 1437279031 CMS profile 110719
1510 12Th Ave Rd, Nampa, ID 83686
General payments
$1,480
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, John Freeman of Nampa, ID is reported in the CMS Open Payments database as having received $1,480 across 89 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 89th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $423 | 24 | |
| 2022 | General | $585 | 33 | |
| 2021 | General | $81 | 5 | |
| 2020 | General | $80 | 6 | |
| 2019 | General | $311 | 21 |
Beside peers
- John Freeman
- Pediatrics median
- Middle half of Pediatrics
- National median
In program year 2025, general payments to John Freeman were reported at $0. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.
Show as a table
| Year | John Freeman | Pediatrics median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $311 | $86 | $31–$183 | $163 |
| 2020 | $80 | $49 | $22–$110 | $114 |
| 2021 | $81 | $68 | $27–$158 | $132 |
| 2022 | $585 | $77 | $30–$173 | $149 |
| 2023 | $423 | $88 | $33–$190 | $160 |
| 2024 | $0 | $94 | $34–$206 | $164 |
| 2025 | $0 | $97 | $37–$210 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 117 drugsPart D claims
6,117
Drug cost
$559,269
Branded share of claims
22.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 125 | $180,598 | |
| Mounjaro Tirzepatide | Brand | 57 | $67,872 | |
| Eliquis Apixaban | Brand | 61 | $66,702 | |
| Farxiga Dapagliflozin Propanediol | Brand | 43 | $56,794 | |
| Trulicity Dulaglutide | Brand | 36 | $38,650 | |
| Xarelto Rivaroxaban | Brand | 13 | $20,639 | |
| Jardiance Empagliflozin | Brand | 12 | $12,496 | |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | Brand | 14 | $8,624 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 202 | $6,952 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 13 | $6,195 |
The 10 drugs with the highest cost, of 117 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 30 billing codesPaid by Medicare
$22,518
Medicare patients
116
Services billed
391
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 66% | |
| Arthritis | 41% | |
| Diabetes | 28% | |
| Chronic kidney disease | 23% | |
| Depression | 22% | |
| Ischemic heart disease | 16% | |
| Osteoporosis | 16% | |
| COPD | 13% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
89 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatrics in Idaho
Related records
Pediatrics in Idaho
Practitioners in the same specialty and state, ranked by reported value.
All Pediatrics
Everyone recorded under this specialty, nationwide.
Doctors in Idaho
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.